Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Just Released: "EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022"


Print article Print article
2013-05-02 01:06:24 - Fast Market Research recommends "EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2022" from GlobalData, now available

Cystic fibrosis (CF) is the most common inherited rare disease in North America and Europe, with more than 27,000 cases in the US and more than 35,000 cases in the European Union (EU) (Cystic Fibrosis Foundation Patient Registry, 2011; Farrell, 2008). CF causes abnormally thick, sticky mucus to accumulate in the respiratory, digestive, and reproductive systems. It is one of the most common chronic lung diseases and is widespread throughout the world. The specific defective gene that cases CF is the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Key differences in the CF epidemiology between countries are influenced by genotype mutations, national screenings, and surveillance systems through national registries. GlobalData forecasts that the US and UK will have the most prevalent

cases of CF in 2022. In 2022, the combined prevalent CF cases in the 5EU countries (France, Germany, Italy, Spain, and the UK) will be slightly larger than the number of prevalent CF cases in the US. The UK and France will have the greatest prevalence proportions (0.0157% and 0.0097%, respectively) and the largest 10-year growth (33.2% and 38.1%, respectively), implying that this may be the result of a higher prevalence of CF gene mutations in these populations. The high number of prevalent cases of CF in the US is due to all 50 states screening for CF in newborns. National CF screenings are imperative in detecting and capturing the true prevalence of the disease in a given country.


Full Report Details at
- www.fastmr.com/prod/591969_epicast_report_cystic_fibrosis_epidem ..


Scope

* The Cystic Fibrosis EpiCast Report provides an overview of the risk factors and comorbidities associated with cystic fibrosis, as well as global trends in prevalence in the six major markets (the US, France, Germany, Italy, Spain, and the UK).
* It also includes a 10-year epidemiological forecast of prevalent cases of cystic fibrosis segmented by sex, age (segmented by five-year age groups, beginning at age 0 years and ending at ages 35 years and older), and mutation type (F508del, G551D, G54X, W1282X, 621+1G>1, R553X, and 3950delT).

Reasons to buy

* Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.
* Quantify patient populations in the global cystic fibrosis market to improve product development, pricing, and launch plans.
* Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for cystic fibrosis therapeutics in each of the markets covered.

Report Table of Contents:

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 The occurrence of cystic fibrosis is approximately one in 2,500 Caucasians 9
3.1.2 Increased cystic fibrosis life expectancy increases comorbidities of CF-related diabetes and bone disease 9
3.2 Global Trends 10
3.2.1 United States 10
3.2.2 France 11
3.2.3 Germany 11
3.2.4 Italy 12
3.2.5 Spain 12
3.2.6 United Kingdom 13
3.3 Forecast Methodology 13
3.3.1 Sources Used 13
3.3.2 Forecast Assumptions and Methods 16
3.3.3 Sources Not Used 19
3.4 Epidemiology Forecast 19
3.4.1 Total Prevalent Cases of Cystic Fibrosis 19
3.4.2 Total Prevalent Cases of Cystic Fibrosis Segmented by Age 21
3.4.3 Total Prevalent Cases of Cystic Fibrosis Segmented by Sex 22
3.4.4 Total Prevalent Cases of Cystic Fibrosis by Mutation Type 23
3.5 Discussion 25
3.5.1 Conclusion on Epidemiology Trends 25
3.5.2 Limitations of the Analysis 25
3.5.3 Strengths of the Analysis 25
4 Appendix 26
4.1 Bibliography 26
4.2 About the Authors 31
4.2.1 Epidemiologists 31
4.2.2 Reviewers 31
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 33
4.2.4 Global Head of Healthcare 33
4.3 About GlobalData 34
4.4 About EpiCast 34
4.5 Contact Us 34
4.6 Disclaimer 35

List of Tables

1.1 List of Tables
Table 1: Six Major Markets, Sources of Cystic Fibrosis Prevalence Data 14
Table 2: Six Major Markets, Sources of Cystic Fibrosis-Causing Mutation Data 14
Table 3: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, Males and Females, Selected Years, 2012-2022 20
Table 4: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, By Sex, 2012 , N (%) 22
Table 5: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0-35 Years, Males and Females, 2012 23

List of Figures

1.2 List of Figures
Figure 1: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, Ages 0-35 Years, Males and Females, Selected Years, 2012-2022 20
Figure 2: Six Major Markets, Total Prevalent Cases of Cystic Fibrosis, By Age, Males and Females, 2012 21
Figure 3: Six Major Markets, Cystic Fibrosis Prevalent Cases Segmented by Mutation Type, Ages 0-35 Years, Males and Females, 2012 24

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com